Do SARMs like Ostarine cause testosterone suppression even at 10 mg per day?

Yes, but suppression at 10 mg/day is mild for most healthy males. Research and self-reported bloodwork suggest LH suppression of roughly 20–40 % compared to baseline — meaningful but typically insufficient to require pharmacological PCT after cycles under 8 weeks. A post-cycle blood panel drawn at weeks 3–4 off-cycle will confirm whether natural recovery has occurred without intervention.

When is a mini-PCT actually necessary after an Ostarine cycle?

A mini-PCT is warranted when post-cycle bloodwork at week 3–4 shows total testosterone below 400 ng/dL alongside LH below 2 mIU/mL. At that point, a 4-week SERM protocol — Enclomiphene 12.5–25 mg/day or Tamoxifen 20 mg tapering to 10 mg — is the standard intervention. Cycles kept at 10 mg for 6–8 weeks often recover naturally without any SERM.

Which bloodwork markers should I test to evaluate suppression after Ostarine?

The three essential markers are serum total testosterone, LH (luteinizing hormone), and FSH (follicle-stimulating hormone). A baseline panel before the cycle and a recovery panel 3–4 weeks post-cycle allow direct comparison. Secondary markers worth including are SHBG and free testosterone to capture the full hormonal picture, especially if subjective symptoms of suppression — fatigue, low libido — persist.

Why choose 10 mg tablets for an Ostarine cycle rather than a higher-dose option?

The 10 mg tablet is the lowest per-tablet dose in the Vital Research SARM line, which gives users maximum flexibility: one tablet equals a complete conservative dose, or two tablets cover the 20 mg mid-range dose without tablet-splitting. This granularity is particularly useful when titrating upward gradually while monitoring bloodwork, minimizing suppression risk at each step.

How long does it take for Ostarine to clear the body, and when should I start PCT?

Ostarine has a half-life of approximately 24 hours, meaning plasma levels drop by half each day. After the final 10 mg tablet, the compound is substantially cleared within 5–7 days. Most practitioners recommend waiting 7–10 days post-cycle before starting a SERM-based mini-PCT, allowing endogenous LH pulsatility to resume naturally — then confirming suppression status with bloodwork before committing to a full SERM protocol. (2) angle_used

Batch Tested

Vital Research

Ostarine 10mg/tab 30 Tablets by Vital Research

Name: Ostarine
Brand: Vital Research
SKU: SARM-OSTA-VIT-003
Price: 42.00 EUR
Availability: InStock

Vital Research Ostarine delivers Ostarine (MK-2866) at 10 mg per tablet across a 30-tablet blister — a low-dose format deliberately suited to monitoring HPTA suppression and calibrating recovery protocols cycle by cycle. At 10 mg, the compound sits below the suppression threshold most users report at 20–25 mg/day, making it practical to assess personal sensitivity before committing to higher doses that typically require post-cycle intervention. Batch-level purity and potency are confirmed through independent HPLC quantification and LAL endotoxin screening; every lot ships with its own traceable certificate of analysis.

€42.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Enables dose-controlled suppression monitoring starting at the lowest effective SARM dose
30-tablet blister provides exactly one standard 4-week conservative cycle or two weeks at 20 mg
Independent HPLC batch verification ensures 10 mg dose accuracy — critical at low concentrations where variance has outsized impact
LAL endotoxin screening on every lot protects against microbiological contamination
Unique lot-coded certificate of analysis accompanies each blister for full traceability
Short 24-hour half-life simplifies post-cycle timing and mini-PCT initiation planning
Selective AR modulation preserves anabolic signaling in muscle tissue while minimizing androgenic side effects

Phase	dosage	Note
Conservative Cycle (Suppression Assessment)	10 mg/day (1 tablet)	Weeks 1–6; draw baseline bloodwork pre-cycle; monitor subjective symptoms weekly
Moderate Cycle	20 mg/day (2 tablets)	Weeks 1–8; increased suppression likelihood — post-cycle bloodwork mandatory
Post-Cycle Observation Window	0 mg (washout)	Days 1–10 after last tablet; allow MK-2866 clearance before assessing LH recovery
Mini-PCT (if bloodwork indicates suppression)	Enclomiphene 12.5–25 mg/day OR Tamoxifen 20→10 mg/day	Weeks 1–4 post-washout; re-test testosterone and LH at end of PCT

Key takeaways

Monitor LH and testosterone bloodwork before starting any PCT decision.
Choose 10 mg tablets to titrate suppression risk dose by dose.
Expect natural recovery within 3–4 weeks at conservative Ostarine doses.
Initiate Enclomiphene or Tamoxifen only when bloodwork confirms suppression.
Verify every batch via HPLC certificate before beginning a cycle.

Does Ostarine Suppress Testosterone — and How Much Does It Matter at 10 mg?

Ostarine (MK-2866) is a selective androgen receptor modulator whose degree of HPTA suppression scales directly with dose and cycle length, making 10 mg/day a clinically relevant starting point for users who want to gather personal suppression data before escalating. Published research (Dalton et al., Phase II trial data) observed measurable but modest LH and FSH suppression at doses of 1–3 mg in elderly populations; extrapolated to the bodybuilding range of 10–25 mg, suppression becomes increasingly pronounced above 15 mg and extends beyond 6 weeks. At the 10 mg dose provided by this Vital Research format, total testosterone suppression in healthy males is typically moderate — serum LH suppression of 20–40 % compared to baseline is commonly self-reported — and generally reversible without pharmacological intervention in cycles under 8 weeks.

Vital Research Ostarine supplies MK-2866 at precisely the dose where suppression remains sub-clinical for most users, enabling a natural recovery window rather than mandatory PCT.

Which Bloodwork Markers Reveal Suppression — and When to Act

Three primary markers determine whether a mini-PCT is warranted: serum total testosterone, LH (luteinizing hormone), and FSH (follicle-stimulating hormone). A post-cycle panel drawn 2–4 weeks after the last tablet provides a suppression snapshot. If total testosterone drops below 400 ng/dL and LH remains below 2 mIU/mL at week 4 of recovery, a structured mini-PCT — typically 4 weeks of Enclomiphene (12.5–25 mg/day) or Tamoxifen (20 mg/day, tapering to 10 mg) — is clinically justified. Compared to post-anabolic-steroid recovery, which routinely requires 6–12 weeks of SERMs plus hCG, a well-timed Ostarine mini-PCT rarely exceeds 4 weeks in duration.

Suppression Recovery Timeline at 10 mg

MK-2866 carries a half-life of approximately 24 hours; plasma clearance is essentially complete within 5–7 days of the last dose. Natural LH pulsatility typically resumes within 1–2 weeks at the 10 mg dose level. Bloodwork at week 3–4 post-cycle determines whether endogenous testosterone has recovered to baseline — if it has, no pharmacological support is needed.

Batch Tested Quality and Dose Precision

Vital Research assigns each 30-tablet Ostarine blister a unique lot code tied to a compound-specific certificate of analysis. HPLC (High-Performance Liquid Chromatography) quantifies MK-2866 content against a certified reference standard; LAL (Limulus Amebocyte Lysate) endotoxin assay confirms microbiological safety independently for every batch. At 10 mg per tablet — the lowest concentration in the Vital Research SARM range — dose precision is especially critical: a 2 mg deviation represents a 20 % variance, which is why independent batch verification is non-negotiable at this concentration.

Usage

Draw a pre-cycle blood panel covering total testosterone, LH, FSH, and SHBG to establish your personal baseline before the first tablet.
Take one 10 mg tablet daily with water, at the same time each day — consistent timing maintains stable plasma levels given the 24-hour half-life.
Keep a weekly log of subjective markers: libido, energy, and recovery quality — early suppression signs often appear before bloodwork changes.
At cycle end, wait 7–10 days (washout period) before drawing a recovery blood panel; this allows MK-2866 plasma clearance and initial natural LH pulsatility.
Compare post-cycle LH, FSH, and total testosterone to baseline: if testosterone is above 400 ng/dL and LH is recovering, observe for another 2 weeks without intervention.
If week 3–4 bloodwork still shows suppression (LH below 2 mIU/mL, testosterone below 400 ng/dL), initiate a 4-week Enclomiphene or Tamoxifen mini-PCT and retest at conclusion.

Warnings

Contraindications: Not intended for use by individuals under 21 years of age, women of childbearing potential, or anyone with pre-existing hypothalamic-pituitary-gonadal axis disorders. Concurrent use with anabolic steroids, prohormones, or other SARMs amplifies suppression risk unpredictably.

Side Effects: Potential effects include dose-dependent testosterone suppression, transient reductions in LH and FSH, mild fatigue during washout, and occasional lipid profile shifts (HDL reduction). These effects are generally reversible upon cessation.

Monitoring: Baseline and post-cycle bloodwork — minimum: total testosterone, LH, FSH — is strongly advised for every cycle regardless of dose. Liver enzyme screening (AST, ALT) is prudent for cycles exceeding 8 weeks.

PCT: Mini-PCT with a SERM (Enclomiphene or Tamoxifen) is recommended when post-cycle bloodwork confirms sustained LH suppression at weeks 3–4. Compared to full steroid PCT, Ostarine recovery protocols are shorter — typically 4 weeks — but should still be evidence-based and bloodwork-guided, not assumed unnecessary.

Frequently asked questions

Do SARMs like Ostarine cause testosterone suppression even at 10 mg per day?: Yes, but suppression at 10 mg/day is mild for most healthy males. Research and self-reported bloodwork suggest LH suppression of roughly 20–40 % compared to baseline — meaningful but typically insufficient to require pharmacological PCT after cycles under 8 weeks. A post-cycle blood panel drawn at weeks 3–4 off-cycle will confirm whether natural recovery has occurred without intervention.
When is a mini-PCT actually necessary after an Ostarine cycle?: A mini-PCT is warranted when post-cycle bloodwork at week 3–4 shows total testosterone below 400 ng/dL alongside LH below 2 mIU/mL. At that point, a 4-week SERM protocol — Enclomiphene 12.5–25 mg/day or Tamoxifen 20 mg tapering to 10 mg — is the standard intervention. Cycles kept at 10 mg for 6–8 weeks often recover naturally without any SERM.
Which bloodwork markers should I test to evaluate suppression after Ostarine?: The three essential markers are serum total testosterone, LH (luteinizing hormone), and FSH (follicle-stimulating hormone). A baseline panel before the cycle and a recovery panel 3–4 weeks post-cycle allow direct comparison. Secondary markers worth including are SHBG and free testosterone to capture the full hormonal picture, especially if subjective symptoms of suppression — fatigue, low libido — persist.
Why choose 10 mg tablets for an Ostarine cycle rather than a higher-dose option?: The 10 mg tablet is the lowest per-tablet dose in the Vital Research SARM line, which gives users maximum flexibility: one tablet equals a complete conservative dose, or two tablets cover the 20 mg mid-range dose without tablet-splitting. This granularity is particularly useful when titrating upward gradually while monitoring bloodwork, minimizing suppression risk at each step.
How long does it take for Ostarine to clear the body, and when should I start PCT?: Ostarine has a half-life of approximately 24 hours, meaning plasma levels drop by half each day. After the final 10 mg tablet, the compound is substantially cleared within 5–7 days. Most practitioners recommend waiting 7–10 days post-cycle before starting a SERM-based mini-PCT, allowing endogenous LH pulsatility to resume naturally — then confirming suppression status with bloodwork before committing to a full SERM protocol. (2) angle_used

Manufacturer

Vital Research's formulation development process treats tablet concentration as a deliberate pharmacological variable rather than a packaging convenience. For the Ostarine line, 10 mg per tablet was selected as the foundational dose point — the level at which users can meaningfully assess personal suppression sensitivity before scaling upward. Achieving consistent 10 mg delivery across all 30 tablets in a blister demands tighter content-uniformity controls than higher-concentration formats, where small manufacturing variances represent a proportionally smaller percentage error. Vital Research addresses this through compound-specific in-process testing at tablet compression, followed by independent HPLC quantification of finished tablets against a certified MK-2866 reference standard. LAL endotoxin assay is applied at batch level, and the resulting compound-specific certificate of analysis is linked to the unique lot code printed on each blister — making every unit's quality data independently verifiable.

Product details

Brand	Vital Research
Active ingredient	ostarine
Also known as	MK-2866, Enobosarm, Ostarine, Vital Research MK-2866
Strength	10 mg
Form	Tabletten
Pack size	30 pieces
Item number	SARM-OSTA-VIT-003

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Ostarine 10mg/tab 60 Tablets by Elbrus Pharmaceuticals

Lab Tested

Ostarine 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Elbrus Pharmaceuticals MK-2866 arrives as a 10mg tablet — a selective androgen receptor modulator purpose-built for body recomposition and lean muscle preservation under caloric restriction. A single 60-tablet pack delivers a complete 8-week beginner cycle at a precision daily dose that keeps suppression risk low while supporting measurable retention of hard-earned muscle tissue. Two independent analytical checkpoints — HPLC potency confirmation on the finished tablet and LAL endotoxin screening — must both clear before any unit ships under an Elbrus lot number.

€60.00

Ostarine 15mg/tab 50 Tablets by Rich Piana 5% Nutrition

HPLC Verified

Ostarine 15mg/tab 50 Tabletten by Rich Piana 5% Nutrition

Rich Piana 5% Nutrition Ostarine delivers 15 mg of MK-2866 per tablet across 50 tablets — engineered as the strategic anchor compound in both goal-phase SARM stacks, whether you are cutting alongside Cardarine or bulking paired with LGD-4033 and RAD-140. At 15 mg per tab, this is the highest per-tablet Ostarine concentration in the current product group, giving stack designers precise, flexible dosing without splitting. Potency is confirmed lot by lot: batch-level HPLC chromatography validates every tablet against its 15 mg label claim before the blister leaves the facility.

€55.00

Top Seller

Ostarine (MK-2866) 10mg/tab 60 Tablets by Master Pharma

Ostarine (MK-2866) is a non-steroidal selective androgen receptor modulator formulated as 10 mg oral tablets, designed to preserve lean muscle and support recomposition without androgenic activity — making it uniquely relevant for gender-specific dosing protocols where virilization risk must be eliminated. Master Pharma supplies 60 tablets per pack, each at the 10 mg concentration that female users can precisely halve via splitting for sub-5 mg introductory phases. Batch release is governed by lot-specific HPLC potency confirmation and LAL endotoxin quantification; both results are recorded on the Certificate of Analysis shipped with every order.

€53.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00